Everything below concerns MC1R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
== Brand names == Aldonil (Zydus Medica), India Aldorin, Bangladesh Alrista (marketed and not manufactured by Macleods), India Epalrica-M (Ordain Global), India Eparel 50 (Microlabs Ltd), India Epimeth (Zaiva Lifesciences), India Eplistat 150 SR (Schem), India Letostat-SR (Amor Pharmaceuticals), India Listap-50 (Vivid Biotek), India Tanglin (Yangtze River Pharmaceutical Group), China
==== Mobile units ==== 1st Special Operations Detachment, 1st Mobile Corps (Falcon Commando Unit, stationed in Beijing) 2nd Special Operations Detachment, 1st Mobile Corps (Overseas Guards Special Operations Detachment, stationed in Tianjin) 3rd Special Operations Detachment, 1st Mobile Corps (stationed in Shijiazhuang) 1st Special Operations Detachment, 2nd Mobile Corps (Snow Leopard Commando Unit, stationed in Guangzhou) 2nd Special Operations Detachment, 2nd Mobile Corps (stationed in Huzhou)
=== Arjo === Arjo was founded in 1957 by Arne Johansson in the Swedish town of Eslöv. The company name consists of the first two letters of the first and last name of the company founder. Arjo initially functioned as a supplier of components and machine parts to medical device manufacturers. In 1972, the company developed the first height-adjustable bathtub and introduced it to the market. In 1993, the company's shares are listed on the Stockholm Stock Exchange and the London Stock Exchange. In 1995, the company merged with the Swedish Getinge Group, in whose "Extended Care" business area it continued to operate under its brand name. In 2004, Arjo took over the company BHM Medical and rounded off its range of passenger lifts with its Ceiling Lifts.
patent 2,666,298 was issued on January 19, 1954 – Methods and means of defrosting a cold diffuser. U.S. patent 2,696,086 was issued on December 7, 1954 – Method and means for air conditioning. U.S. patent 2,780,923 was issued on February 12, 1957 – Method and means for preserving perishable foodstuffs in transit. U.S. patent 2,850,001 was issued on September 2, 1958 – Control device for internal combustion engine. U.S. patent 2,926,005 was issued on February 23, 1960 – Thermostat and temperature control system.
Sources: en.wikipedia.org
== Dental education == The institution operates its medical education under the name the West China School of Stomatology. This arrangement combines undergraduate and postgraduate dental education with patient care and research. The school offers undergraduate programs including a four-year dental-technology program, a five-year dental medicine program and an eight-year clinical medicine and dentistry track. It also provides master's and doctoral education and clinical training for international students. The academic structure encompasses basic oral sciences, operative dentistry and oral medicine, oral and maxillofacial surgery, prosthodontics, orthodontics and interdisciplinary oral sciences. The institution also operates national-level experimental and virtual-simulation teaching platforms. West China's historical influence on Chinese dental education has been widely noted. A study of dental education before 1949 described the 1917-established dental school at West China Union University as China's earliest institution dedicated to educating dentists. University of Toronto historical collections similarly identify the West China program as an important channel through which modern dental teaching methods were introduced into China. The institution operates two museums: the West China Museum of Stomatology (华西口腔医学博物馆) and the West China Museum of Stomatological Health Education (华西口腔健康教育博物馆). The stomatology museum was established in 1932 as the Dental Medicine Hall of the Museum of West China Union University (华西协合大学博物馆医牙馆).
Duane Tolbert Gish (February 17, 1921 – March 5, 2013) was an American biochemist and a prominent member of the creationist movement. A young Earth creationist, Gish was a former vice-president of the Institute for Creation Research (ICR) and the author of numerous publications about creation science. Gish was called "creationism's T. H. Huxley" for the way he "relished the confrontations" of formal debates with prominent evolutionary biologists, usually held on university campuses, while abandoning formal debating principles, in a style that came to be known as the Gish gallop. A creationist publication noted in his obituary that "it was perhaps his personal presentation that carried the day. In short, the audiences liked him."
=== Motility and chemotaxis === The vertical motility of neutrophils in capillary tubes is stimulated by tuftsin, stimulation is inhibited by Thr-Lys-Pro-Pro-Arg. The tuftsin analogue Thr-Pro-Lys-Arg failed to show stimulation.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.